Our policy panel will discuss these findings at their November 2019 meeting and agree what we think as an organisation and our next steps.
When it comes to evidence of the benefits of cannabis-based products for people with Parkinson’s, the jury is definitely out.
Most people currently using cannabis-derived products, or those who had used them in the past, didn’t get advice from professionals beforehand. Those who did are split on whether the advice was helpful.
What products are people using?
There’s a lot more research needed, both in the lab and in clinical trials.
Cannabis is a class-B controlled drug in the UK. Possessing, producing and supplying it are all against the law. ‘Supply’ includes sharing the drug with someone or giving it (even for free) to friends or relatives.
In fact, we’re funding a clinical trial through our Virtual Biotech right now. In a world first clinical trial, Professor Sagnik Bhattacharyya and Dr Latha Velayudhan at Kings College London (KCL) will be testing whether cannabidiol (CBD) can treat Parkinson’s psychosis symptoms.
Between January and March 2019, we asked people with Parkinson’s and health professionals to tell us about their experiences with and opinions on using cannabis-based products.
CBD is a compound found in the cannabis plant. Unlike another component, THC, CBD is non-addictive and doesn’t cause intoxication. You may have already heard of it because of its potential as a treatment for epilepsy and multiple sclerosis.
The Parkinson’s Virtual Biotech is our best chance of turning promising discoveries into real treatments for people with Parkinson’s.
Our Virtual Biotech operates in the same way but instead of doing it for profit, like a standard biotech, we’re doing it for people affected by Parkinson’s. We don’t own our own labs, hi-tech specialist equipment or employ a team of scientists because this would be enormously expensive. Instead, we’re taking an efficient approach. Partnering with institutions and pharmaceutical companies worldwide that already have the expertise, tools and infrastructure. In a chronically underfunded area, this means more money can be put into promising treatments.
This project is the first clinical trial to go through the Virtual Biotech and the 6th project overall.
In a world first clinical trial, researchers will test whether cannabidiol (CBD) can treat Parkinson’s psychosis symptoms with the help of the Virtual Biotech.
This article will help you understand the potential benefits of using CBD oil for Parkinson’s Disease on top of highlighting the best companies whose products actually work.
Psychosis is a sort of collateral damage caused by Parkinson’s disease. It can lead to hallucinations, delusions, and delirium. It is more likely to occur during the later stages of the disease and affects up to 50 percent of people with PD.
How Could CBD Oil Help with Parkinson’s?
Parkinson’s disease (PD) is a neurological condition that impacts a person’s nervous system, usually appearing at the age of 60. In simple words, brain cells that release the neurotransmitter dopamine — which sends messages to the body about the movement — become damaged and start to degenerate.
Prescription medications to alleviate the symptoms of the disease may be effective, but they tend to lose efficacy over time, requiring larger doses to provide relief — which often leads to adverse side effects such as drowsiness, blurred vision, lightheadedness, nausea, vomiting, diarrhea, dry mouth, heartburn, loss of appetite, and more.
Other health problems in people with PD include: